Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients

Journal of Psychopharmacology

Volumn 21, Issue 7, 2007, Pages 728-734

  Bozina, Nada ^a,b   Medved, Vesna ^b   Kuzman, Martina Rojnic ^b   Sain, Ivica ^c   Sertic, Jadranka ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b KBC Zagreb   (Croatia)

^c brankarestek petrovic pbsvihr   (Croatia)

Author keywords

Genetics; Olanzapine; Schizophrenia; Serotonin transporters; Treatment response; Weight gain

Indexed keywords

BIPERIDEN; CLONAZEPAM; DIAZEPAM; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN TRANSPORTER; SULPIRIDE;

ADULT; AGED; AKATHISIA; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SUBSTITUTION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEREDITY; HUMAN; HYPERPROLACTINEMIA; INTRON; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROMOTER REGION; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ALLELES; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CROATIA; FEMALE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 34548760167     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881106072750     Document Type: Article

References (51)

1. Allison D.B. and Casey D.E. (2001) Antipsychotic weight gain: a review of the literature. J Clin Psychiatry 62: 22 - 31
2. Bagnall A.M., Jones L., Ginnelly L., Lewis R., Glanville J., Gilbody S., Davies L., Torgerson D., Kleijnen J. (2003) A systematic review of antipsychotic drugs in schizophrenia. Health Techno Assess 7 (13). 1 - 193
3. Benton D. (2004) Role of parents in the determination of the food preferences of children and the development of obesity. Int J Obes Relat Metab Disord 28: 858 - 869
4. Cohen D. (2004) Atypical antipsychotics and new onset of diabetes mellitus. Pharmacopsychiatry 37: 1 - 11
5. Collier D.A., Stober G., Li T., Heils A., Catalano M., Di Bella D., Arranz M.J., Murray R.M., Vallada H.P., Bengel D., Muller C.R., Roberts G.W., Smeraldi E., Kirov G., Sham P., Lesch K.P. (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1: 453 - 460
6. Coyle N., Jones I., Robertson E., Lendon C., Craddock N. (2000) Variation at the serotonin transporter gene influences susceptibility to bipolar affective puerperal psychosis. Lancet 356: 1490 - 1491
7. Dubertret C., Hanoun N., Adès J., Hamon M., Gorwood P. (2005) Family-based association study of the 5-HT transporter gene and schizophrenia. International Journal of Neuropsychopharmacology 8: 87 - 92
8. Excoffier L., Laval G., Schneider S. (2006) Arlequin ver. 3.01: An Integrated Software Package for Population Genetic Data Analysis. University of Bern, Switzerland
9. Fan J.B., Sklar P. (2005) Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Mol Psychiatry 10: 928 - 938
10. Fuller R.W. (1994) Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 55: 163 - 167
11. Gelenrter J., Cubells J.F., Kidd J.R., Pakstis A.J., Kidd K.K. (1999) Population studies of polymorphisms of the serotonin transporter protein gene. Am J Med Genet 88: 61 - 66
12. Golimbet V.E., Alfimova M.V., Shchebatykh T.V., Abramova L.I., Kaleda V.G., Rogaev E.I. (2004) Serotonin transporter polymorphism and depressive-related symptoms in schizophrenia. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 126: 1 - 7
13. Graham K A., Perkins D O., Edwards L J., Barrier R.C. Jr, Lieberman J A., Harp J B. (2005) Effects of olanzapine on body composition and energy expenditure in adults with first-episode psyhosis. Am J Psychiatry 162: 118 - 123
14. Guo S.W., Thompson E.A. (1992) Performing the exact test of Hardy-Weinberg proportions for multiple alleles. Biometrics 48: 361 - 372
15. Haddad P. (2005) Weight change with atypical antipsychotics in the treatment of schizophrenia. Journal of Psychopharmacology 19: 16 - 27
16. Hanna G.L., Himle J A., Curtis G C., Koram D Q., Veenstra-VanderWeele J., Leventhal B L., Cook E.H. Jr (1998) Serotonin transporter and serotonin transporter promoter affects onset of paroxetine treatment seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 18: 102 - 111
17. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., Lesch K.P. (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621 - 2624
18. Herken H., Erdal M.E., Aynacioglu A.S., Barlas O., Cataloluk O., Esgi K., Brockmoller J., Kaiser R. (2002) Frequency of the 17-bp variable number of tandem repeat polymorphism in Turkish schizophrenic patients. Schizophr Res 58: 99 - 100
19. Holm S. (1979) A simple sequentially rejective multiple test procedure. Scand J Stat 6: 65 - 70
20. Hong C.J., Lin C.H., Yu Y.W., Yang K.H., Tsai S.J. (2001) Genetic variant of the serotonin system and weight change during clozapine treatment. Pharmacogenetics 11: 265 - 268
21. Hranilovic D., Stefulj J., Furac I., Kubat M., Balija M., Jernej B. (2003) Serotonin transporter gene promoter (5-HTTLPR) and intron 2 (VNTR) polymorphisms in croatian suicide victims. Biol Psychiatry 54: 884 - 889
22. Ito K., Yoshida K., Sato K., Takahashi H., Kamata M., Higuchi H., Shimizu T., Itoh K., Inoue K., Tezuka T., Suzuki T., Ohkubo T., Sugawara K., Otani K. (2002) A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine. Psychiatry Res 111: 235 - 239
23. Jacobs B.L., Fornal C.A. (1995) Serotonin and behaviour: a general hypothesis. In Bloom F E, Kupfer D J (eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press, New York
24. Koch S., Perry K.W., Bymaster F.P. (2004) Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 46: 232 - 242
25. Kunugi H., Hattori M., Kato T., Tatsumi M., Sakai T., Sasaki T., Hirose T., Nanko S. (1997) Serotonin trasporter gene polymorphism: ethnic difference and possible associations with bipolar affective disorder. Mol Psychiatry 2: 457 - 462
26. Lee I M., Paffenbarger R.S. Jr (1992) Changes in body weight and longevity. JAMA 268: 2045 - 2049
27. Lesch K.P. (2001) Variation of serotonergic gene expression: neurodevelopment and the complexity of response to psychopharmacologic drugs. European Neuropsychopharmacology 11: 457 - 474
28. Lesch K.P., Balling U., Gross J., Strauss K., Wolozin B.L., Murphy D.L., Riederer P. (1994) Organization of the human serotonin transporter gene. J Neural Transm Gen Sect 95: 157 - 162
29. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hammer D.H., Murphy D.L. (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region, Science 274: 1527 - 1531
30. MacKenzie A., Quinn J. (1999) A serotonin transporter gene intone 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 96: 15251 - 15255
31. Magni P., Liuzzi A., Ruscica M., Dozio E., Ferrerio S., Bussi I., Minocci A., Castagna A., Motta M., Savia G. (2005) Free and bound plasma leptin in normal weight and obese men and women: relationship with body composition, resting energy expenditure, insulin-sensitivity, lipid profile and macronutrient preference. Clin Endocrinol (Oxf) 62: 189 - 196
32. Masand P.S., Gupta S. (1999) Selective serotonine-reputake inhibitors: an update. Harv Rev Psychiatry 7: 69 - 84
33. Mendes de Oliveira J R., Otto P A., Vallada H., Lauriano V., Elkis H., lafer B., Vasquez L., Gentil V., Passos-Bueno M R., Zatz M. (1998) Analysis of a novel functional polymorphism within the promoter region of the serotonin transporter gene (5-HTT) in Brasilian patients affected by bipolar disorders and schizophrenia. Am J Med Genet 81: 225 - 227
34. Miller S.A., Dykes D.D., Polesky H.F. (1988) A simple salting out procedure for extracting DNA from human nucleated cell. Nucl Acid Res 16: 1215
35. Müller D.J., Muglia P., Fortune T., Kennedy J.L. (2004) Pharmacogenetics of antipsychotic-induced weight gain. Pharmacological Research 49: 309 - 329
36. National Institutes of Health Consensus Development Panel on the Health Implications of Obesity (1985) Health implications of obesity. Ann Intern Med 103: 1073 - 1077
37. Ramamoorthy S., Giovanetti E., Qian Y, Blakely (1998). Phosphorylation and regulation of antidepressant-sensitive serotonin transporters. J Biol Chem 273: 2458 - 2466
38. Rausch J.L., Johnson M.E., Fei Y.J., Li J.Q., Shendarkar N., Hobby H.M., Ganapathy V., Leibach F.H. (2002) Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI trial outcome. Biol Psychiatry 51: 723 - 732
39. Reynolds G.P., Zhang Z.J., Zhang X.B. (2002) Association of antipsychotic weigt gain with a 5-HT2C polymorphism. Lancet 359: 2086 - 2087
40. Rice W.R. (1989) Analyzing tables of statistical tests. Evolution 43: 223 - 225
41. Routh V.H., Stern J.S., Horwitz B.A. (1994) Serotonergic activity is depressed in the ventromedial hypothalamic nucleus of 12-day-old obese Zucker rats. American Journal of Physiology 267: R712 - R719
42. Serretti A., Lilli R., Smeraldi E. (2002) Pharmacogenetics in affective disorders. European Journal of Pharmacology 438: 117 - 128
43. Slatkin M., Excoffier L. (1996) Testing for linkage disequilibrium in genotypic data using the EM algorithm. Heredity 76: 377 - 383
44. Smeraldi E., Benedetti F., Zanardi R. (2002) Serotonin transporter promoter genotype and illness recurrence in mood disorders. European Neuropsychopharmacology 12: 73 - 75
45. Søeby K., Larsen S.A., Olsen L., Rasmussen H.B., Werge T. (2005) Serotonin transporter: evolution and impact of polymorphic transcriptional regulation. American Journal of Medical Genetics Part B (Neuropsychiatric Genetics) 136B: 53 - 57
46. Stober G., Jatzke S., Heils A., Jungkunz G., Fuchs E., Knapp M., Riederer P., Lesch K.P. (1998) Susceptibility for schizophrenia is not influenced by a functional insertion/deletion variant in the promoter of the serotonin transporter gene. Eur Arch Psychiatry Clin Neurosci 248: 82 - 86
47. Tandon R., Jibson M.D. (2003) Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9 - 26
48. Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F., Julius D. (1995) Eating disorder and epilepsy in mice lacking 5-HT2C serotonine receptors. Nature 374: 542 - 546
49. Templeman L.A., Reynolds G.P., Arranz B., San L. (2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenetics and Genomics 15: 195 - 200
50. Tsai S.J., Hong C.J., Yu Y.W., Lin C.H., Song H.L., Lai H.C., Yang K.H. (2000) Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response. Schizophr Res 44: 177 - 181
51. Wurtman R.J., Wurtman J.J. (1998) Serotoninergic mechanisms and obesity. J Nutr Biochem 9: 511 - 515